It is a third-generation variant of the blood-boosting drug EPO, which increases the ability of a user's blood to carry oxygen.
All products eventually die, but the most successful ones live long enough to produce at least one 'offspring' -- a next generation product or a same-generation variant.
The best second-generation variant was subjected to another round of ep-PCR, and an improved third-generation variant was identified.
The only "second-generation" variant is the double mutant N96W + H222R (number 10 in Table 2) that was expressed because the single mutant N96W had a high experimental affinity and H222R showed neutral binding behavior, while these two single mutations are sequentially distant so that we assumed that they might influence each other the least.
The most successful products will generate many same-generation variants and a chain of next generation products.
In the current study, the ease in detecting additional chromosome changes in our analysis of second-generation variants supports the possibility of general genome instability in CBS7779.
Analogues such as the ones described here, and next-generation variants, are potential adjuncts to insulin therapy that will allow coformulation with insulin.
We have discussed ongoing community efforts to address these challenges, including clinical-grade sample collection, digitalized phenotyping, acquisition of high-quality sequencing data, rigorous generation of variant calls, comprehensive functional annotation of variants, and biological validation of variant function.
In particular, we urge the need for clinical-grade sample collection, high-quality sequencing data acquisition, digitalized phenotyping, rigorous generation of variant calls, and comprehensive functional annotation of variants.
